[Behavior of LH, FSH, total testosterone, free testosterone and SHBG serum levels in the therapy of prostatic cancer with Turisteron (ethinyl estradiol sulfonate)].
45 patients with prostatic cancer were treated conservatively with Turisteron at a dosage of 2 mg per week. After 2 months the serum levels of total testosterone were reduced to castration values and thereafter furthermore to 6% of the pretreatment values. The free testosterone (FT) serum level did show a decrease to 2%, while the binding capacity of the sexual hormone binding globulin (SHBG) was increased from 4,1% to 97,9%. The serum levels of the two gonadotropic hormones luteinizing hormone (LH) and follicle-stimulating hormone (FSH) were decreased only to nearly 20% of the pretreatment value. The investigations confirm the definite "antiandrogenic" effect of Turisteron, which is 10-times higher than the antigonadotropic effect.
D004997:Ethinyl Estradiol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005640:Follicle Stimulating Hormone / Q000097:blood; D005500:Follow-Up Studies; D012739:Gonadal Steroid Hormones / Q000097:blood*; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy*; D012738:Sex Hormone-Binding Globulin / Q000378:metabolism; D013739:Testosterone / Q000097:blood
D012739:Gonadal Steroid Hormones; D012738:Sex Hormone-Binding Globulin; C025723:ethinyl estradiol sulfonate; D013739:Testosterone; D004997:Ethinyl Estradiol; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone
Das Verhalten der Serumspiegel von LH, FSH, Gesamttestosteron (GT), freiem Testosteron (FT) und SHBG unter der Therapie des Prostatakarzinoms mit Turisteron (Ethinylestradiolsulfonat).